| 000 | 01822 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250515130104.0 | ||
| 264 | 0 | _c20081006 | |
| 008 | 200810s 0 0 eng d | ||
| 022 | _a1523-4681 | ||
| 024 | 7 |
_a10.1359/jbmr.080312 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBolland, Mark J | |
| 245 | 0 | 0 |
_aEffects of intravenous zoledronate on bone turnover and BMD persist for at least 24 months. _h[electronic resource] |
| 260 |
_bJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research _cAug 2008 |
||
| 300 |
_a1304-8 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aBone Density _xdrug effects |
| 650 | 0 | 4 |
_aBone Density Conservation Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aBone and Bones _xdrug effects |
| 650 | 0 | 4 |
_aDiphosphonates _xadministration & dosage |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 |
_aHIV Infections _xphysiopathology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImidazoles _xadministration & dosage |
| 650 | 0 | 4 | _aInjections, Intravenous |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPlacebos |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 | _aZoledronic Acid |
| 700 | 1 | _aGrey, Andrew B | |
| 700 | 1 | _aHorne, Anne M | |
| 700 | 1 | _aBriggs, Simon E | |
| 700 | 1 | _aThomas, Mark G | |
| 700 | 1 | _aEllis-Pegler, Rod B | |
| 700 | 1 | _aCallon, Karen E | |
| 700 | 1 | _aGamble, Greg D | |
| 700 | 1 | _aReid, Ian R | |
| 773 | 0 |
_tJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research _gvol. 23 _gno. 8 _gp. 1304-8 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1359/jbmr.080312 _zAvailable from publisher's website |
| 999 |
_c18108220 _d18108220 |
||